AA
MRSN

AlphaCentric Advisors’s Mersana Therapeutics MRSN Stock Holding History

AlphaCentric Advisors’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,620
Closed -$618K – 255
2021
Q3 		$618K Buy
2,620
+800
+44% +$234K 0.16% 57
2021
Q2 		$618K Buy
1,820
+600
+49% +$227K 0.17% 52
2021
Q1 		$493K Buy
1,220
+1,036
+563% +$503K 0.17% 47
2020
Q4 		$122K Buy
184
+70
+61% +$38.9K 0.05% 102
2020
Q3 		$53K Buy
+114
New +$57.6K 0.03% 100

Other funds holding MRSN

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return